CD40 agonistic-monovalent streptavidin fusion antibody for targeted neoantigen peptide delivery and potent cancer vaccination
Jung, D.; Cai, X.; Wan, Z.; Lee, N.; Ramseier, N. T.; Hu, Y.; Lim, S.-O.; Lee, S. S.-Y.
Show abstract
Cancer vaccines targeting patient-derived neoantigens offer great promise for personalized cancer therapy but face challenges in achieving targeted delivery to antigen-presenting cells (APCs) to elicit robust and durable cancer-specific immune responses. We synthesized an anti-mouse CD40 agonistic-monovalent streptavidin fusion antibody (CD40-mSAs), which enables targeted delivery of biotinylated neoantigen peptides to APCs in draining lymph nodes (dLNs). We confirmed mSA expression on the engineered antibody and its strong binding affinities to mouse CD40 and biotin. Advanced microscopy demonstrated that CD40-mSAs enhances homing to dLNs and intracellular delivery of neoantigen peptides to critical APC subsets, such as cDC1. The potent agonistic effects of CD40-mSAs on dendritic cell maturation, activation, and antigen presentation were verified through in vitro assays. Vaccination with CD40-mSAs elicited robust cancer-specific CD8 T cell responses, leading to significant tumor regression and prevention in a mouse tumor model. These results support CD40-mSAs as an all-in-one vaccine delivery platform with multifunctional immunopharmacological advantages and strong translational potential for personalized cancer vaccination. TeaserCD40-mSAs is an engineered anti-CD40 agonistic antibody designed to enhance cancer vaccine delivery.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Polymeric Pathogen-like Particles-Based Combination Adjuvants Elicit Potent Mucosal T Cell Immunity to Influenza A Virus 95%
- Combination of a Sindbis-SARS-CoV-2 spike vaccine and αOX40 antibody elicits protective immunity against SARS-CoV-2 induced disease and potentiates long-term SARS-CoV-2-specific humoral and T-cell immunity 95%
- Single-domain antibodies for targeting, detection and in vivo imaging of human CD4+ cells 95%
Similar papers in this journal
- Langerhans Cell-targeted Protein Delivery Enhances Antigen-Specific Cellular Immune Response 96%
- A Single Dose of Self-Transcribing and Replicating RNA Based SARS-CoV-2 Vaccine Produces Protective Adaptive Immunity In Mice 96%
- mRNA-LNP vaccines against Hepatitis B virus induce protective immune responses in preventive and chronic mouse challenge models 94%
Similar papers in this journal
- Bedside formulation of a personalized multi-neoantigen vaccine against mammary carcinoma 97%
- A Mimicry-Based Strategy Between Human and Commensal Antigens for the Development of a New Family of Immune Therapies for Cancer 96%
- Novel personalized cancer vaccine platform based on Bacillus Calmette-Guerin 96%
Similar papers in this journal
- Vaccination with mycobacterial lipid loaded nanoparticle leads to lipid antigen persistence and memory differentiation of antigen-specific T cells 97%
- PRR adjuvants restrain high stability peptides presentation on APCs 96%
- Unraveling the Power of NAP-CNB's Machine Learning-enhanced Tumor Neoantigen Prediction 95%
Similar papers in this journal
- Dextran-based T-cell expansion nanoparticles for manufacturing CAR T cells with augmented efficacy 95%
- Single-dose avian influenza A(H5N1) Clade 2.3.4.4b hemagglutinin-Matrix-M nanoparticle vaccine induces neutralizing responses in nonhuman primates 95%
- A stabilized MERS-CoV spike ferritin nanoparticle vaccine elicits robust and protective neutralizing antibody responses 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.